ArticleTherapeutic advances in medical oncology2026

Sequential or upfront triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma: the MONTBLANC trial protocol (AIO-HEP-0325/ass).

Najib Ben Khaled et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.